Knut Brockow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Knut Brockow has a total of 252 co-authors. Here are the top co-authors by number of shared publications:
J. Ring
11 shared publicationsJohannes Ring
Technical University of Munich
5 shared publicationsHans F. Merk
4 shared publicationsWerner Aberer
Medical University of Graz
4 shared publicationsBernhard Przybilla
Ludwig Maximilian University of Munich
3 shared publications- Bettina Wedi
Department of Dermatology and Allergy, Comprehensive Allergy Center, Hannover Medical School, Hannover, Germany
3 shared publications
Latest Publications
- 1 November 2022
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 45 (11) , 812-822
Organisation und Erkenntnisse einer Pilotstudie zur allergologischen Abklärung einer COVID-19-Impfstoffallergie in der Weihnachtswoche 2021
- 1 November 2022
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 45 (11) , 812-822
Organisation und Erkenntnisse einer Pilotstudie zur allergologischen Abklärung einer COVID-19-Impfstoffallergie in der Weihnachtswoche 2021
- Open Access
- 30 January 2018
- Published by Springer Nature in Allergo Journal
- Vol. 27 (1) , 40-41
Erratum zu: Leitlinie Allergologische Diagnostik von Überempfindlichkeitsreaktionen auf Arzneimittel
- 30 January 2018
- Published by Springer Nature in Allergo Journal
- Vol. 27 (1) , 40-41
Open AccessErratum zu: Leitlinie Allergologische Diagnostik von Überempfindlichkeitsreaktionen auf Arzneimittel
- 22 September 2017
- Published by Springer Nature in Allergo Journal
- Vol. 26 (6) , 12
Negativer Hauttest ≠ Antibiotikatoleranz
- 22 September 2017
- Published by Springer Nature in Allergo Journal
- Vol. 26 (6) , 12
Negativer Hauttest ≠ Antibiotikatoleranz
- 1 March 2016
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 39 (3) , 125-136
Leitlinie Allergologische Diagnostik von Überempfindlichkeitsreaktionen auf Arzneimittel
- 1 March 2016
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 39 (3) , 125-136
Leitlinie Allergologische Diagnostik von Überempfindlichkeitsreaktionen auf Arzneimittel
- Open Access
- 9 May 2015
- Published by Springer Nature in Allergo Journal International
- Vol. 24 (3) , 94-105
Guideline for the diagnosis of drug hypersensitivity reactions
Drug hypersensitivity reactions are unpredictable adverse drug reactions. They manifest either within 1–6 h following drug intake (immediate reactions) with mild to life-threatening symptoms of anaphylaxis, or several hours to days later (delayed reactions), primarily as exanthematous eruptions. It is not always possible to detect involvement of the immune system (allergy). Waiving diagnostic tests can result in severe reactions on renewed exposure on the one hand, and to unjustified treatment restrictions on the other. With this guideline, experts from various specialist societies and institutions have formulated recommendations and an algorithm for the diagnosis of allergies. The key principles of diagnosing allergic/hypersensitivity drug reactions are presented. Where possible, the objective is to perform allergy diagnostics within 4 weeks–6 months following the reaction. A clinical classification of symptoms based on the morphology and time course of the reaction is required in order to plan a diagnostic work-up. In the case of typical symptoms of a drug hypersensitivity reaction and unequivocal findings from validated skin and/or laboratory tests, a reaction can be attributed to a trigger with sufficient confidence. However, skin and laboratory tests are often negative or insufficiently reliable. In such cases, controlled provocation testing is required to clarify drug reactions. This method is reliable and safe when attention is paid to indications and contraindications and performed under appropriate medical supervision. The results of the overall assessment are discussed with the patient and documented in an „allergy passport“ in order to ensure targeted avoidance in the future and allow the use of alternative drugs where possible.
- 9 May 2015
- Published by Springer Nature in Allergo Journal International
- Vol. 24 (3) , 94-105
Open AccessGuideline for the diagnosis of drug hypersensitivity reactions
Drug hypersensitivity reactions are unpredictable adverse drug reactions. They manifest either within 1–6 h following drug intake (immediate reactions) with mild to life-threatening symptoms of anaphylaxis, or several hours to days later (delayed reactions), primarily as exanthematous eruptions. It is not always possible to detect involvement of the immune system (allergy). Waiving diagnostic tests can result in severe reactions on renewed exposure on the one hand, and to unjustified treatment restrictions on the other. With this guideline, experts from various specialist societies and institutions have formulated recommendations and an algorithm for the diagnosis of allergies. The key principles of diagnosing allergic/hypersensitivity drug reactions are presented. Where possible, the objective is to perform allergy diagnostics within 4 weeks–6 months following the reaction. A clinical classification of symptoms based on the morphology and time course of the reaction is required in order to plan a diagnostic work-up. In the case of typical symptoms of a drug hypersensitivity reaction and unequivocal findings from validated skin and/or laboratory tests, a reaction can be attributed to a trigger with sufficient confidence. However, skin and laboratory tests are often negative or insufficiently reliable. In such cases, controlled provocation testing is required to clarify drug reactions. This method is reliable and safe when attention is paid to indications and contraindications and performed under appropriate medical supervision. The results of the overall assessment are discussed with the patient and documented in an „allergy passport“ in order to ensure targeted avoidance in the future and allow the use of alternative drugs where possible.
- 8 May 2015
- Published by Springer Nature in Allergo Journal
- Vol. 24 (3) , 44-57
Leitlinie Allergologische Diagnostik von Überempfindlichkeitsreaktionen auf Arzneimittel
- 8 May 2015
- Published by Springer Nature in Allergo Journal
- Vol. 24 (3) , 44-57
Leitlinie Allergologische Diagnostik von Überempfindlichkeitsreaktionen auf Arzneimittel
- 1 August 2014
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 34 (3) , 547-564
Hypersensitivity to Contrast Media and Dyes
- 1 August 2014
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 34 (3) , 547-564
Hypersensitivity to Contrast Media and Dyes
- 17 July 2014
- Published by Springer Nature
- p. 97-104
Drug Intolerance
- 1 July 2014
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 37 (7) , 258-264
Kofaktorgetriggerte Nahrungsmittelanaphylaxie
- 1 July 2014
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 37 (7) , 258-264
Kofaktorgetriggerte Nahrungsmittelanaphylaxie
- 1 July 2014
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 37 (07) , 301-308
Management der Anaphylaxie – Aktuelles aus der Leitlinie
- 1 July 2014
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 37 (07) , 301-308
Management der Anaphylaxie – Aktuelles aus der Leitlinie